drugset / Trial / NCT05313750

Efficacy and Safety of Sitafloxacin in the Treatment of Acute Exacerbation of Bronchiectasis in Adults

NCT05313750

Phase 4 Unknown 256 enrolled Shanghai Pulmonary Hospital, Shanghai, China
RandomizedParallel-groupOpen-labelTreatment

Summary

The treatment of acute exacerbation of bronchiectasis requires comprehensive treatment, and antibacterial drug therapy is the key. The study is a multicenter, randomized, evaluator-blinded, levofloxacin parallel-controlled clinical study designed to evaluate the efficacy and safety of sitafloxacin in the treatment of acute exacerbations of bronchiectasis in adults.

Timeline

Start
2021-06-30
Primary completion
2023-12-30
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levofloxacin Small molecule 0.4 g Oral
Subject SITAFLOXACIN ANHYDROUS Small molecule 0.1 g Oral

Indications